ATE295355T1 - Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen - Google Patents

Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen

Info

Publication number
ATE295355T1
ATE295355T1 AT99917863T AT99917863T ATE295355T1 AT E295355 T1 ATE295355 T1 AT E295355T1 AT 99917863 T AT99917863 T AT 99917863T AT 99917863 T AT99917863 T AT 99917863T AT E295355 T1 ATE295355 T1 AT E295355T1
Authority
AT
Austria
Prior art keywords
tris
substituted
treatment
triazine derivatives
hiv infections
Prior art date
Application number
AT99917863T
Other languages
English (en)
Inventor
Frederik Frans Desire Daeyaert
Corte Bart De
Jonge Marc Rene De
Jan Heeres
Chih Yung Ho
Paul Adriaan Jan Janssen
Robert W Kavash
Lucien Maria Henricus Koymans
Michael Joseph Kukla
Donald William Ludovici
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE295355T1 publication Critical patent/ATE295355T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/50—Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/66—Derivatives of melamine in which a hetero atom is directly attached to a nitrogen atom of melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99917863T 1998-03-27 1999-03-24 Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen ATE295355T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7963398P 1998-03-27 1998-03-27
EP98201589A EP0945447A1 (de) 1998-03-27 1998-05-14 Trisubstituierte 1,3,5-Triazinderivate zur Behandlung von HIV Infektionen
PCT/EP1999/002044 WO1999050256A1 (en) 1998-03-27 1999-03-24 Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections

Publications (1)

Publication Number Publication Date
ATE295355T1 true ATE295355T1 (de) 2005-05-15

Family

ID=22151790

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99917863T ATE295355T1 (de) 1998-03-27 1999-03-24 Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen

Country Status (32)

Country Link
US (3) US6150360A (de)
EP (2) EP0945447A1 (de)
JP (1) JP2002511390A (de)
KR (1) KR100593396B1 (de)
CN (1) CN1157386C (de)
AP (1) AP1475A (de)
AR (1) AR018169A1 (de)
AT (1) ATE295355T1 (de)
AU (1) AU758624C (de)
BG (1) BG64903B1 (de)
BR (1) BR9909197A (de)
CA (1) CA2324921C (de)
DE (1) DE69925256T2 (de)
DK (1) DK1066269T3 (de)
EA (1) EA004540B1 (de)
EE (1) EE200000535A (de)
ES (1) ES2243056T3 (de)
HR (1) HRP20000621A2 (de)
HU (1) HUP0101372A3 (de)
ID (1) ID26043A (de)
IL (1) IL138670A (de)
NO (1) NO317425B1 (de)
NZ (1) NZ506787A (de)
OA (1) OA11493A (de)
PL (1) PL194660B1 (de)
PT (1) PT1066269E (de)
SI (1) SI1066269T1 (de)
SK (1) SK14052000A3 (de)
TR (1) TR200002761T2 (de)
TW (1) TW570917B (de)
WO (1) WO1999050256A1 (de)
ZA (1) ZA200006042B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4919566B2 (ja) * 1999-09-24 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗ウイルス組成物
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
US6645964B1 (en) * 1999-11-29 2003-11-11 Aventis Pharma S.A. Chemical derivatives and their application as antitelomerase agent
US20020065270A1 (en) * 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
US6943161B2 (en) * 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
US6906067B2 (en) * 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
DK1282607T3 (en) 2000-05-08 2016-02-01 Janssen Pharmaceutica Nv Prodrugs of HIV replication inhibiting pyrimidines
JP5230050B2 (ja) 2000-05-08 2013-07-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ複製阻害剤
US6858608B2 (en) * 2001-01-09 2005-02-22 Aventis Pharma S.A. Chemical derivatives and their application as antitelomerase agents
US6887873B2 (en) * 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7132423B2 (en) * 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7169785B2 (en) * 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
NZ532349A (en) * 2001-09-21 2007-02-23 Reddy Us Therapeutics Inc Methods and compositions of novel triazine compounds
AU2002342018A1 (en) * 2001-10-12 2003-04-28 New York University Trisubstituted triazines compounds with antitubulin activity
WO2003037346A1 (en) * 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
AU2003244463A1 (en) * 2002-02-05 2003-09-02 Yamanouchi Pharmaceutical Co., Ltd. 2,4,6-triamino-1,3,5-triazine derivative
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
US20070232572A1 (en) * 2003-02-07 2007-10-04 Aventis Pharma S.A. Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent
KR20050105190A (ko) * 2003-02-07 2005-11-03 얀센 파마슈티카 엔.브이. Ｈｉｖ를 저해하는 1,2,4-트리아진
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
US6875781B2 (en) * 2003-04-04 2005-04-05 Cell Therapeutics, Inc. Pyridines and uses thereof
US20060172010A1 (en) 2003-07-17 2006-08-03 Gael Lamoureux Process for preparing particles containing an antiviral
WO2005009980A1 (en) * 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
US7335770B2 (en) * 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
JP5031564B2 (ja) * 2004-08-10 2012-09-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ抑制１，２，４−トリアジン−６−オン誘導体
BRPI0516746A (pt) 2004-09-30 2008-09-23 Tibotec Pharm Ltd 5-heterociclil pirimidinas para inibição de hiv
KR20070057798A (ko) 2004-09-30 2007-06-07 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 저해하는 5-탄소환 또는 복소환으로 치환된피리미딘
ES2380631T3 (es) 2004-09-30 2012-05-17 Tibotec Pharmaceuticals Pirimidinas sustituidas en posición 5 inhibidoras de VIH
WO2006045828A1 (en) 2004-10-29 2006-05-04 Tibotec Pharmaceuticals Ltd. Hiv inhibiting bicyclic pyrimidine derivatives
US7592451B2 (en) * 2005-06-23 2009-09-22 New York University Treatment for diabetes and obesity as well as method of screening compounds useful for such treatments
WO2007071199A1 (en) * 2005-12-22 2007-06-28 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences 2,4-disubstituted amido-6-substituted-[1,3,5]triazine or 1,3-pyrimidine compounds, their processes for preparation, their pharmaceutical compositions and uses thereof
ES2465666T3 (es) 2006-03-30 2014-06-06 Janssen R&D Ireland Pirimidinas 5-amido-sustituidas inhibidoras del HIV
BRPI0720858B8 (pt) 2006-12-29 2021-05-25 Janssen R & D Ireland pirimidinas 6-substituídas inibidoras de hiv e composição farmacêutica que as compreende
ES2523863T3 (es) 2006-12-29 2014-12-02 Janssen R&D Ireland Pirimidinas 5,6-sustituidas inhibidoras del VIH
US8835629B2 (en) 2010-10-27 2014-09-16 The Walter And Eliza Hall Institute Of Medical Research Anti-cancer agents
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US9914709B2 (en) * 2013-06-21 2018-03-13 Yale University Compositions and methods of treating HIV-1 infections using same
WO2015144881A1 (en) * 2014-03-28 2015-10-01 Basf Se Diaminotriazine derivatives as herbicides
PT3394040T (pt) 2015-12-24 2022-03-24 Univ California Reguladores de cftr e seus métodos de uso
CN111629730A (zh) 2017-08-24 2020-09-04 加利福尼亚大学董事会 眼部药物组合物
CN109053613A (zh) * 2018-07-04 2018-12-21 复旦大学 含有联苯结构的二芳基三嗪类化合物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2742466A (en) * 1956-04-17 Chx n nhx c c
US2671810A (en) * 1952-05-24 1954-03-09 Du Pont Long-chain diketones
BE754242A (fr) * 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US4096206A (en) * 1976-02-09 1978-06-20 Borg-Warner Corporation Flame-retardant triazines
US4652645A (en) 1983-11-16 1987-03-24 Ciba-Geigy Corporation Cationic compounds
EP0541966A3 (en) * 1991-11-15 1994-09-07 American Cyanamid Co Process for preparing amide derivatives from halomines and acid halides
US5283274A (en) * 1992-06-19 1994-02-01 Uniroyal Chemical Company, Inc. Substituted pyrimidines and substituted triazines as rubber-to-metal adhesion promoters
PL313973A1 (en) 1993-10-12 1996-08-05 Du Pont Merck Pharma 1 n-alkyl-n-arylopyrimidin amines and their derivatives
GB9519197D0 (en) * 1995-09-20 1995-11-22 Affinity Chromatography Ltd Novel affinity ligands and their use
CN1163401A (zh) * 1996-02-13 1997-10-29 李占元 全自动血球计数仪试剂及配制方法
WO1999036410A1 (en) * 1998-01-13 1999-07-22 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds

Also Published As

Publication number Publication date
IL138670A (en) 2005-12-18
WO1999050256A1 (en) 1999-10-07
KR100593396B1 (ko) 2006-06-28
US6150360A (en) 2000-11-21
US6372729B1 (en) 2002-04-16
OA11493A (en) 2004-05-07
SK14052000A3 (sk) 2001-06-11
AR018169A1 (es) 2001-10-31
AU3599799A (en) 1999-10-18
BG64903B1 (bg) 2006-08-31
AU758624B2 (en) 2003-03-27
NZ506787A (en) 2003-02-28
US20020115668A1 (en) 2002-08-22
HK1032394A1 (en) 2001-07-20
PT1066269E (pt) 2005-09-30
HUP0101372A2 (hu) 2001-10-28
EA004540B1 (ru) 2004-06-24
NO317425B1 (no) 2004-10-25
TR200002761T2 (tr) 2001-01-22
AP2000001913A0 (en) 2000-09-30
SI1066269T1 (en) 2005-10-31
AU758624C (en) 2004-03-11
ZA200006042B (en) 2001-10-26
CN1157386C (zh) 2004-07-14
EP0945447A1 (de) 1999-09-29
CA2324921A1 (en) 1999-10-07
DE69925256D1 (de) 2005-06-16
EP1066269B1 (de) 2005-05-11
BR9909197A (pt) 2000-12-05
AP1475A (en) 2005-10-03
NO20004809L (no) 2000-11-24
PL343195A1 (en) 2001-07-30
ID26043A (id) 2000-11-16
JP2002511390A (ja) 2002-04-16
NO20004809D0 (no) 2000-09-26
PL194660B1 (pl) 2007-06-29
BG104716A (en) 2001-04-30
DK1066269T3 (da) 2005-09-05
ES2243056T3 (es) 2005-11-16
HRP20000621A2 (en) 2001-04-30
CA2324921C (en) 2009-05-12
EP1066269A1 (de) 2001-01-10
EA200000993A1 (ru) 2001-04-23
CN1295566A (zh) 2001-05-16
TW570917B (en) 2004-01-11
KR20010034270A (ko) 2001-04-25
HUP0101372A3 (en) 2003-02-28
EE200000535A (et) 2002-04-15
US6774235B2 (en) 2004-08-10
DE69925256T2 (de) 2006-02-23

Similar Documents

Publication Publication Date Title
ATE295355T1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
EA200000840A1 (ru) Антивирусные производные пиримидина
DE60219292D1 (de) Pyrazolderivate zur behandlung von hiv
NO20013369D0 (no) Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
BR9902086A (pt) Formulações farmacêuticas.
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
EP1001782A4 (de) 5,6-HETEROARYL-DIPYRIDO (2-3-b:3',2'-f) AZEPINE UND DEREN VERWENDUNG ZUR PROPHYLAXE UND BEHANDLUNG VON HIV-INFEKTIONEN
DE69936285D1 (de) INDOLOi2,1-BöQUINAZOLIN-6,12-DIONE ANTIMALARIA DERIVATE UND METHODEN ZUR BEHANDLUNG VON MALARIA
ATE298569T1 (de) Virus behandlung
DE60006412D1 (de) Oxazinochinolone zur behandlung von viralen infektionen
NO20032769L (no) Kombinasjonsmetode for behandling av virale infeksjoner
DE59910146D1 (de) Topisch anwendbares arzneimittel zur behandlung von virusinfektionen
NO20012540D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
PY0101564A (es) Triazine containing anionic compounds useful as antiviral agents
ATE316374T1 (de) Antikonvulsive derivate zur behandlung von essentiellem tremor
DE59904904D1 (de) Verfahren zur Herstellung von Phenyldichloro-1,3,5-triazinverbindungen
ATE261965T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien
IT1320401B1 (it) Procedimento per la fabbricazione di componenti di un'ossatura ecomponenti di ossatura.
IL138670A0 (en) Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections
ITRM990762A0 (it) Procedimento per la preparazione di filati ondee o compensina.
NO20006686D0 (no) Fremgangsmåte for fremstilling av ammoniakk
ZA993346B (en) The treatment of viral infections.
DK1122245T3 (da) 2-Aminobenzoxazinoner til behandling af virale infektioner

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1066269

Country of ref document: EP

REN Ceased due to non-payment of the annual fee